The U.S. Food and Drug Administration has given the green light for Mabwell Therapeutics to launch a clinical trial testing 9MW3811, its injectable treatment candidate for idiopathic pulmonary fibrosis (IPF) and cancer, according to a company press release. Last month, the National Medical Products Administration in…

Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat…

The first healthy volunteer has been dosed in a trial evaluating ISM001-055, Insilico Medicine’s artificial intelligence (AI)-discovered therapy candidate for idiopathic pulmonary fibrosis (IPF). “We are very pleased to see Insilico Medicine’s first antifibrotic [treatment] candidate entering into the clinic,” Feng Ren, PhD, Insilico’s chief strategy officer, said…

Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1 trial of healthy volunteers. Developed by Blade Therapeutics, cudetaxestat is designed to block the activity of an enzyme called autotaxin that produces a pro-scarring (fibrotic) signaling molecule. This enzyme commonly…

LYT-100 (deupirfenidone), an experimental oral therapy containing a similar active ingredient to Esbriet, was well-tolerated at all tested doses — and did not reach the maximum tolerated dose or MTD — in a Phase 1 trial conducted in healthy volunteers. PureTech Health, which is developing LYT-100 for…

DWN12088, an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase 1 clinical trial that enrolled healthy volunteers. Daewoong Pharmaceutical, the therapy’s developer, now plans to start a Phase 2 trial later this year. “We…

The French Medicines Agency has authorized Genkyotex to launch a Phase 1 trial to evaluate the safety and pharmacological properties of high-dose setanaxib, the company’s investigational oral treatment for idiopathic pulmonary fibrosis (IPF). Setanaxib (formerly known as GKT831) is an investigational anti-fibrotic therapy that is thought…

A new small molecule inhibitor of the LOXL2 enzyme, developed by Pharmaxis, is safe and holds potential to treat fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non‐alcoholic steatohepatitis (NASH), according to results from a Phase 1 trial. The study (ACTRN12617001564347) enrolled 48 healthy volunteers who were…